---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-007952"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T01:37:47.050640+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharmaceuticals enters new employment agreements with five officers, including CEO at $675k salary

## Summary
- CEO A.J. Kazimi base salary set at $675,000; effective January 1, 2023.
- EVP James Herman salary $310,000; VP Todd Anthony $272,500; VP Chris Bitterman $258,500; CFO John Hamm $228,000.
- All agreements are at-will with no severance for cause, death, or permanent disability.
- No change-in-control or termination provisions; include non-compete, non-solicitation, confidentiality covenants.
- Agreements dated March 9, 2023, effective retroactively to January 1, 2023.

## SEC filing metadata
- accession: 0001628280-23-007952
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828023007952/0001628280-23-007952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828023007952/cpix-20230315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-007952
- JSON: https://secwatch.observer/filing/0001628280-23-007952.json
- Plain text: https://secwatch.observer/filing/0001628280-23-007952.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.